Etiketter

Summa sidvisningar

Leta i den här bloggen

måndag 7 februari 2011

Sartaanien etu diabeteksessa

Betasolu-uutisista löytyy seuraava maininta angiotensiiniblokkarin eduista, sillä se on betasoluprotektiivinen koska lisää betasolusaarekkeen mikroverenkiertoa ja täten parantaa insuliinin erityymisfunktiotat.

HAKUSANA PubMed: Betacell ( tarkoituksena seuloa esiin uutisia )

LÄHDE: J Huazhong Univ Sci Technolog Med Sci. 2009 Dec;29(6):684-8. Epub 2009 Dec 29. Effect of renin angiotensin system blockade on the islet microvessel density of diabetic rats and its relationship with islet function.

Li X, Yuan L, Xu G, Qi C, Li J, Li H, Cheng S. Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Abstract ( suomennosta)
Tutkittiin reniini-angiotensiinijärjestelmän blokeerauksen vaikutuksia diabeettisen koe-eläimen (DM ryhmä) betasolusaarekkeitten mikroverisuonien tiheyteen. Sitten tehtiin interventiotutkimus käyttäen 8 viikkoa perindopriilia (AE ryhmä) tai valsartaania (AR ryhmä) . Sitten arvioitiin saarekkeitten toiminta insuliinin laskimonsisäisestä vapautumisesta. Saareke arvioitiin sitten immunohistokemiallisesti ja insuliinin sekä kasvutekijän VEGF määrät katsottiin. Mikrosuonimäärä laskettiin CD34-positiivisista soluista. Myös HIF-1alfa mRNA mitattiin ( hypoxia inducible factor)

To investigate the effects of renin angiotensin system blockade on the microvessel density in islets of diabetic rats and its relationship with islet function, diabetes model was created by feeding of high-caloric laboratory chow plus intraperitoneal injection of a small dose of streptozotocin (30 mg/kg).

After 8 weeks intervention with perindopril (AE, n=10) or valsartan (AR, n=10), the islet function of the animals was evaluated by intravenous insulin release test (IVIRT). The pancreases were immunohistochemically stained to analyze the content of insulin and vascular endothelial growth factor (VEGF) in the islets. The microvessel density (MVD) of islets was detected by counting CD34 positive cells. The hypoxia inducible factor (HIF)-1alpha mRNA expression in the islets was detected by RT-PCR.

Compared with normal control group (NC, n=10), the area under the curve for insulin from 0 to 30 min (AUCI(0-30)) of diabetes group (DM, n=8) was decreased by 66.3%; the insulin relative concentration (IRC) of betacell was decreased significantly; the relative content of VEGF was increased obviously [(-4.21+/-0.13) vs (-4.06+/-0.29)]; MVD in islets was decreased by 71.4%; the relative expression of HIF-1alpha mRNA was increased by 1.19 times (all P<0.01).>

Compared with DM group, the AUCI(0-30) of AE and AR group was increased by 44.6% and 34.9% respectively; IRC was also increased significantly; the relative content of VEGF was decreased by 21.2% and 21.7% respectively; MVD was increased by 62.5% and 75.0% respectively; the relative expression of HIF-1alpha was decreased by 27.2% and 29.0% respectively (all P<0.01>

There were no significant differences in the said indexes between group AE and AR.
It is concluded that the blockade of RAS may ameliorate islets function of diabetic rats by increasing the MVD in islets.

  • JOHTOPÄÄTÖS
Indekseissä ei ollut eroja oli siiten -priiliryhmän tai -sartaaniryhmän interventioaine kyseessä. RAS blokadin katsotaan parantavan betasolusaarekkeitten funktiota diabeettisissa koe-eläimissä saarekkeitten verenkiertoa (mikroverisuonitiheyttä) lisäämällä.

Inga kommentarer: